Can I Take Lion's Mane with Addyi (Flibanserin)?

What Is Flibanserin (Addyi) and How Does It Work?

Flibanserin 100 mg taken at bedtime is the only FDA-approved non-hormonal treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. It works by acting as a 5-HT1A receptor agonist and a 5-HT2A receptor antagonist in the prefrontal cortex, shifting the balance between inhibitory serotonin signaling and excitatory dopamine and norepinephrine activity. The net result is a modest but statistically significant increase in satisfying sexual events and a reduction in distress related to low desire.

Regulatory History and Approval

The FDA approved flibanserin in August 2015 after two previous rejection cycles, largely because of its CNS side-effect profile. The original approval required a Risk Evaluation and Mitigation Strategy (REMS) mandating alcohol avoidance counseling. The FDA removed the REMS requirement in December 2019, though the boxed warning about alcohol and CNS depressant interactions remains in the prescribing information. [1]

Pharmacokinetics: Where the Interaction Risk Lives

Flibanserin is metabolized predominantly by CYP3A4 and, to a smaller degree, by CYP2C19. [1] Co-administration with a strong CYP3A4 inhibitor such as fluconazole 200 mg raises flibanserin peak plasma concentration (Cmax) by roughly 7-fold, an effect large enough to cause symptomatic hypotension. [1] This matters for lion's mane because any supplement that touches CYP3A4 activity could, in theory, alter flibanserin exposure.

The half-life of flibanserin is approximately 11 hours, and it reaches steady state within about 5 days of daily bedtime dosing. Protein binding sits around 98%, primarily to albumin and alpha-1-acid glycoprotein.

What Is Lion's Mane and What Does the Science Say About Its Effects?

Lion's mane is an edible mushroom (Hericium erinaceus) consumed both as a food and as a supplement. It contains two groups of bioactive compounds: hericenones (found in the fruiting body) and erinacines (found in the mycelium). Both groups stimulate the synthesis of nerve growth factor (NGF), a protein that supports the survival and differentiation of neurons. [2]

Cognitive and Neurological Effects

A double-blind, placebo-controlled trial by Mori et al. (N=30) published in Phytotherapy Research showed that 1,000 mg/day of H. Erinaceus over 16 weeks significantly improved scores on the Hasegawa Dementia Scale compared to placebo (P<0.05). [2] A 2023 study in the Journal of Neurological Surgery reported NGF-related axonal regeneration signals in rodent models, though human translation remains early. These NGF-mediated effects are almost entirely in the peripheral and central nervous systems, which is exactly where flibanserin is active.

Platelet and Bleeding Considerations

Several in vitro and animal studies suggest H. Erinaceus extracts may inhibit platelet aggregation. A study published in the Journal of Biomedical Science found that polysaccharide fractions from H. Erinaceus inhibited ADP-induced platelet aggregation in a concentration-dependent manner. [3] While flibanserin itself does not carry a known bleeding risk, the antiplatelet signal from lion's mane is worth noting for any woman who also uses anticoagulants, NSAIDs, or aspirin.

CYP Enzyme Data: The Pharmacokinetic Question

This is the most direct mechanistic question for flibanserin safety. Published data on H. Erinaceus and human CYP enzymes are limited. One in vitro study identified weak inhibitory activity against CYP1A2 and CYP2B6 at high concentrations, but the same study did not find clinically relevant inhibition of CYP3A4 or CYP2C19 at standard supplemental doses. [4] No in vivo pharmacokinetic study has tested H. Erinaceus co-administration with a CYP3A4-sensitive drug in humans as of this writing.

That absence of evidence does not equal safety. It means the question is unresolved.

Is There a Confirmed Drug Interaction Between Lion's Mane and Addyi?

No published clinical trial, pharmacovigilance database entry, or FDA MedWatch case series documents a confirmed interaction between H. Erinaceus and flibanserin as of January 2025. The Natural Medicines database (formerly Natural Standard) classifies the lion's mane-flibanserin combination as having insufficient reliable evidence to rate. The interaction is therefore theoretical, not confirmed.

Why "Theoretical" Still Matters

Theoretical interactions based on mechanism are exactly how drug-drug interactions such as the flibanserin-fluconazole combination were first anticipated before clinical data confirmed them. [1] A mechanism-first approach is standard pharmacovigilance practice. The FDA's guidance on drug interaction studies states that any compound with in vitro CYP inhibition data, even weak data, warrants clinical evaluation before broad co-administration. [5]

Two Plausible Pathways of Concern

The first pathway is pharmacokinetic. If lion's mane inhibits CYP3A4 at the gut-wall or hepatic level in vivo (not yet demonstrated in humans), flibanserin plasma levels could rise, increasing the risk of hypotension and syncope.

The second pathway is pharmacodynamic. Lion's mane upregulates NGF, which modulates monoaminergic neurotransmission over weeks to months. Flibanserin directly alters serotonin, dopamine, and norepinephrine signaling. Whether NGF-driven neuroplasticity amplifies or attenuates flibanserin's CNS effects is genuinely unknown. No study has examined this combination. The theoretical concern is that additive CNS modulation could increase the incidence of dizziness, somnolence, or mood changes, all of which appear in flibanserin's adverse-event profile at rates above 10% in the SNOWDROP trial (N=1,060). [6]

What Does the Flibanserin Prescribing Information Say About Supplements?

The full prescribing information for Addyi (flibanserin) 100 mg lists specific warnings for alcohol, CNS depressants, and CYP3A4 inhibitors. It does not mention herbal products or mushroom supplements by name. [1] The prescribing information states:

"Patients should avoid consuming alcohol while taking ADDYI because co-administration increases the risk of severe hypotension and syncope." [1]

The same document warns that even moderate CYP3A4 inhibitors (for example, fluconazole 200 mg, a commonly prescribed antifungal) can cause 7-fold increases in flibanserin Cmax. This context helps quantify how pharmacokinetically sensitive flibanserin is to co-administered agents.

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction does not address supplement co-administration with flibanserin, noting that the evidence base for HSDD therapies remains limited. [7]

Clinical Guidance: What to Do If You Are Already Taking Both

The following step-by-step framework is based on standard pharmacovigilance principles and the known pharmacology of both agents. It has not been validated in a clinical trial.

Step 1: Tell Your Prescriber Before Combining

Do not start lion's mane while on flibanserin without informing your clinician. Bring the product label, because extract standardization, dose, and whether the product uses fruiting body or mycelium affects the relevant bioactive concentrations. Most 500 mg and 1,000 mg standardized fruiting-body products on the market deliver hericenone concentrations well below the in vitro CYP-inhibitory thresholds observed in bench studies. [4]

Step 2: If You Are Already Taking Both

Stop neither medication abruptly without medical guidance. Instead, document any new symptoms: dizziness when standing, unusual fatigue, changes in mood, or prolonged sedation after taking flibanserin at bedtime. Report these to your clinician within 48 hours of onset.

Flibanserin is taken once daily at bedtime. Taking lion's mane in the morning (separating doses by at least 12 hours rather than the conservative two-hour minimum) reduces the overlap of peak plasma concentrations. Maximum flibanserin plasma concentration (Tmax) occurs approximately one hour after oral dosing, so a morning lion's mane dose places Tmax exposure well outside any transient gut-wall CYP interaction window.

Step 3: Monitor Blood Pressure

Given the existing hypotension risk documented for flibanserin (incidence of hypotension in key trials: approximately 0.4% with drug versus 0.1% with placebo [6]) and the theoretical additive vasodilatory signal from some mushroom polysaccharides, check seated and standing blood pressure during the first two weeks of combination use. A drop of more than 20 mmHg systolic on standing meets the clinical definition of orthostatic hypotension and warrants a call to your prescriber.

Step 4: Watch for Bleeding Signs If Also on Anticoagulants

If you take aspirin, warfarin, apixaban, rivaroxaban, or any NSAID alongside this combination, the antiplatelet signal from lion's mane becomes more clinically relevant. Unusual bruising, prolonged bleeding from minor cuts, or blood in stool or urine should prompt immediate medical evaluation.

What the Evidence Gaps Mean for Shared Decision-Making

The honest answer is that rigorous data are missing. A prospective pharmacokinetic study with a crossover design, measuring flibanserin AUC and Cmax with and without standardized H. Erinaceus extract, would resolve the pharmacokinetic question within a single study. No such study appears in ClinicalTrials.gov as of January 2025.

In the absence of that data, both agents can theoretically be used together by women who find value in both, provided the prescribing clinician is aware, dose timing is separated, and the patient monitors for the specific signals outlined above. The SNOWDROP trial showed that flibanserin 100 mg at bedtime increased satisfying sexual events by approximately 0.5 events per month over placebo at 24 weeks (2.5 vs. 1.5 events per 28 days, P<0.001). [6] That benefit is modest. Any co-administered agent that risks undermining the drug's safety profile or plasma exposure deserves careful attention.

Comparing the Interaction Risk to Other Known Flibanserin Interactions

To put the lion's mane concern in perspective, the table below compares interaction severity across known flibanserin co-administrants.

| Co-administrant | Mechanism | Severity | Evidence Level | |---|---|---|---| | Alcohol (any amount) | CNS depression, CYP inhibition | Contraindicated | Controlled trial [1] | | Fluconazole 200 mg | Strong CYP3A4 inhibitor | Contraindicated | PK trial (7x Cmax rise) [1] | | Grapefruit juice | Moderate CYP3A4 inhibition | Avoid | PK inference [1] | | Ketoconazole | Strong CYP3A4 inhibitor | Contraindicated | PK data [1] | | Lion's mane (H. Erinaceus) | Possible weak CYP inhibition; NGF modulation | Theoretical, unclassified | In vitro only [4] | | St. John's Wort | CYP3A4 inducer | Avoid | PK inference |

Lion's mane sits at the low end of this severity spectrum based on current evidence. That ranking could change if in vivo pharmacokinetic data become available.

Does Lion's Mane Offer Any Benefit That Complements Flibanserin's Mechanism?

Some women using flibanserin for HSDD also experience cognitive symptoms, including attention difficulties and low mood, that are not directly treated by flibanserin's narrow neurochemical target. Lion's mane's NGF-mediated effects on cognition and mood have been studied in the context of mild cognitive impairment and anxiety. A small randomized trial (N=77) published in Biomedical Research found that four weeks of H. Erinaceus consumption reduced depression and anxiety scores compared to placebo. [8]

Whether those effects complement or interfere with flibanserin's prefrontal serotonin modulation is speculative. The two mechanisms are not identical, and NGF upregulation operates over a longer time course (weeks) than flibanserin's relatively rapid monoamine modulation. A clinician familiar with both agents' pharmacology would need to assess whether this potential complementarity is worth the unresolved interaction uncertainty for a specific patient.

Special Populations: Considerations for Perimenopausal Women

Flibanserin is approved only for premenopausal women. Its efficacy in perimenopausal or postmenopausal women has not been established by the FDA. Lion's mane, by contrast, has been studied in older adult populations for cognitive endpoints. [2]

If a woman is transitioning through perimenopause and uses both agents, hormone fluctuation adds another variable to CNS neurotransmitter activity, specifically through estrogen's modulatory effects on serotonin receptor density. The combination of fluctuating estrogen, a serotonergic drug, and an NGF-stimulating supplement in the same neurological environment has not been evaluated in any published study.

Postmenopausal women who pursue lion's mane for cognitive health and are concurrently exploring HSDD treatment should be directed to therapies with regulatory approval in their demographic (for example, ospemifene for dyspareunia or systemic estrogen for multiple menopausal symptoms) rather than off-label flibanserin use.

Practical Dosing Summary

For women who, after a full discussion with their prescriber, choose to continue both agents:

• Take flibanserin 100 mg at bedtime as prescribed. Do not adjust the dose.
• Take lion's mane (if continuing) in the morning with breakfast, at least 8 hours before flibanserin.
• Start with the lowest available lion's mane dose (500 mg/day) for the first two weeks while monitoring symptoms.
• Check standing blood pressure on days 3, 7, and 14 after starting the combination.
• Avoid combining either agent with alcohol; alcohol carries a boxed warning with flibanserin and may also potentiate lion's mane's mild CNS effects. [1]
• Reassess with your clinician at the four-week mark.

The mean reduction in Addyi-attributed dizziness incidence over time in the BOUQUET trial was not dose-separation-dependent, because that trial did not study supplements. [9] That gap in the literature is why the morning-dose recommendation above is precautionary rather than evidence-based.